Advances in Chronic Kidney Disease
Volume 17, Issue 1 , Pages 19-25 , January 2010

HIV and CKD Epidemiology

  • Jonathan A. Winston

      Affiliations

    • Corresponding Author InformationAddress correspondence to Jonathan Winston, MD, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1243, New York, NY 10029.

References 

  1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 1–139. US Department of Health and Human Services. 2008;
  2. Mugavero MJ, Lin HY, Allison JJ, et al. Racial disparities in HIV virologic failure: Do missed visits matter?. J Acquir Immune Defic Syndr. 2009;50:100–108
  3. U.S. Renal Data System. USRDS 2008 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: Bethesda, Maryland, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2008;
  4. Szczech LA, Grunfeld C, Scherzer R, et al. Microalbuminuria in HIV infection. AIDS. 2007;21:1003–1009
  5. Szczech LA, Gange SJ, van der Horst C, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int. 2002;61:195–202
  6. Choi AI, Rodriguez RA, Bacchetti P, et al. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol. 2007;18:2968–2974
  7. Lucas GM, Lau B, Atta MG, et al. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: A tale of two races. J Infect Dis. 2008;197:1548–1557
  8. Overton ET, Nurutdinova D, Freeman J, et al. Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy. HIV Med. 2009;10:343–350
  9. Campbell LJ, Ibrahim F, Fisher M, et al. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med. 2009;10:329–336
  10. Fine DM, Perazella MA, Lucas GM, et al. Kidney biopsy in HIV: beyond HIV-associated nephropathy. Am J Kidney Dis. 2008;51:504–514
  11. U.S. Renal Data System. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007;
  12. Stehman-Breen CO, Gillen D, Steffes M, et al. Racial differences in early-onset renal disease among young adults: The coronary artery risk development in young adults (CARDIA) study. J Am Soc Nephrol. 2003;14:2352–2357
  13. Hsu CY, Lin F, Vittinghoff E, et al. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol. 2003;14:2902–2907
  14. Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 2004;66:1145–1152
  15. Stohr W, Walker AS, Munderi P, et al. Estimating glomerular filtration rate in HIV-infected adults in Africa: Comparison of Cockcroft-Gault and Modification of Diet in Renal Disease formulae. Antivir Ther. 2008;13:761–770
  16. Wools-Kaloustian K, Gupta SK, Muloma E, et al. Renal disease in an antiretroviral-naive HIV-infected outpatient population in Western Kenya. Nephrol Dial Transplant. 2007;22:2208–2212
  17. Emem CP, Arogundade F, Sanusi A, et al. Renal disease in HIV-seropositive patients in Nigeria: An assessment of prevalence, clinical features and risk factors. Nephrol Dial Transplant. 2008;23:741–746
  18. Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol. 2005;16:180–188
  19. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179–1184
  20. Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 2005;19:1375–1383
  21. Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS. 2007;21:1739–1745
  22. Gazzaruso C, Bruno R, Garzaniti A, et al. Hypertension among HIV patients: Prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens. 2003;21:1377–1382
  23. Jung O, Bickel M, Ditting T, et al. Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrity. Nephrol Dial Transplant. 2004;19:2250–2258
  24. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296
  25. Wyatt CM, Winston JA, Malvestutto CD, et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS. 2007;21:2101–2103
  26. Young B, Buchacz K, Baker RK, et al. Renal function in tenofovir-exposed and tenofovir-unexposed patients Receiving Highly Active Antiretroviral Therapy in the HIV Outpatient Study. J Int Assoc Physicians AIDS Care (Chic Ill). 2007;6:178–187
  27. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572
  28. Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care. 2004;27(suppl 1):S79–S83
  29. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559–1585
  30. Gardner LI, Holmberg SD, Williamson JM, et al. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:203–209
  31. Gardner LI, Klein RS, Szczech LA, et al. Rates and risk factors for condition-specific hospitalizations in HIV-infected and uninfected women. J Acquir Immune Defic Syndr. 2003;34:320–330
  32. Szczech LA, Hoover DR, Feldman JG, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis. 2004;39:1199–1206
  33. Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant. 2006;21:2809–2813
  34. Ross MJ, Klotman PE. HIV-associated nephropathy. AIDS. 2004;18:1089–1099
  35. Szczech LA, Edwards LJ, Sanders LL, et al. Protease inhibitors are associated with a slowed progression of HIV- related renal diseases. Clin Nephrol. 2002;57:336–341
  36. Winston JA, Bruggeman LA, Ross MD, et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med. 2001;344:1979–1984
  37. El-Sadr WM, Grund B, Neuhaus J, et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med. 2008;149:289–299
  38. Mocroft A, Wyatt C, Szczech L, et al. Interruption of antiretroviral therapy is associated with increased plasma cystatin C. AIDS. 2009;23:71–82
  39. Shlipak MG, Cystatin C. research priorities targeted to clinical decision making. Am J Kidney Dis. 2008;51:358–361
  40. Kalayjian RC, Franceschini N, Gupta SK, et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS. 2008;22:481–487
  41. Mauss S, Berger F, Kuschak D, et al. Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients. Antivir Ther. 2008;13:1091–1095
  42. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23:689–696
  43. Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10:482–487
  44. Moore RD, Gallant J: Renal function after use of tenofovir as part of the initial ART regimen. Washington, DC, 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). October 25-28, 2008 (abstr #H2297)
  45. Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS. 2008;22:2155–2163
  46. Wyatt CM, Malvestutto C, Coca SG, et al. The impact of hepatitis C virus coinfection on HIV-related kidney disease: A systematic review and meta-analysis. AIDS. 2008;22:1799–1807
  47. Tsui J, Vittinghoff E, Anastos K, et al. Hepatitis C seropositivity and kidney function decline among women with HIV: Data from the Women's Interagency HIV Study. Am J Kidney Dis. 2009;54:43–50

 Dr Winston is a member of the Speaker's Bureau of Gilead Sciences. He receives consulting and lecture fees.

PII: S1548-5595(09)00165-7

doi: 10.1053/j.ackd.2009.08.006

Advances in Chronic Kidney Disease
Volume 17, Issue 1 , Pages 19-25 , January 2010

Article Tools